Market research
3HY.F Arix Bioscience plc
F EUR Healthcare
Latest close
As of 06 Feb 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 218M
- P/E ratio
- 12.38
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.05
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 218M
- P/E ratio
- 12.38
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.05
About
About Arix Bioscience plc
Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, novel therapeutics, innovative technologies, medical innovation comprising healthcare and life sciences. It seeks to invest globally. The firm employs an evergreen approach to funding. It primarily makes investments from its own balance sheet. The firm prefers to take board seat. The firm exit when the optimum value has been reached. Arix Bioscience plc is formerly known as Perceptive Bioscience Investments Limited. Arix Bioscience plc was founded in 2015 and is based in London, United Kingdom.
Research context
Arix Bioscience plc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 3HY.F discussion.
5 years, 6 months ago
Arix Bioscience plc is currently in a long term uptrend where the price is trading 2.0% above its 200 day moving average.
From a valuation standpoint, the stock is 60.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 517.9.
Finally, its free cash flow grew by 36.5% to $-1M since the same quarter in the previous year.
Based on the above factors, Arix Bioscience plc gets an overall score of 3/5.